Trinity Biotech (TRIB) said Tuesday it has secured $5.5 million in additional liquidity through amended agreements with Perceptive Advisors, including cash and payment-in-kind interest.
As part of the agreement, Trinity has granted Perceptive 1.5 million additional warrants to buy its American depositary shares and repriced its existing warrants to $0.80 per ADS, Trinity added.
A $5 million deferred payment tied to its acquisition of Waveform Technologies assets was also extended to November 2025, increasing its financial flexibility, Trinity Biotech said.
The liquidity will support the company's transformation plan, including its World Health Organization-approved transition to offshore manufacturing for TrinScreen HIV and Uni-Gold HIV, Trinity Biotech said.
Trinity Biotech were up more than 10% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。